CD274 and gastric cancer: Taken together, these findings support a biologically coherent, blood-based tool that captures complementary information beyond conventional clinicopathologic features and PD-L1 CPS, offering a practical framework for risk stratification and individualized prognostication in the chemo-immunotherapy era for advanced GC.